Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial (Q39107888)

9 September 2017

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial (English)

1 reference

multicenter clinical trial

9 September 2017

0 references

phase II clinical trial

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jens Bedke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Marc-Oliver Grimm

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Padmanee Sharma

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Margitta Retz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Arlene Siefker-Radtke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ari Baron

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elizabeth R Plimack

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Daniel Vaena

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sergio Bracarda

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

José Ángel Arranz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sumanta Pal

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Chikara Ohyama

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Abdel Saci

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Xiaotao Qu

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alexandre Lambert

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Suba Krishnan

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alex Azrilevich

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Matthew D Galsky

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

25 January 2017

1 reference

Lancet Oncology Commission

9 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

312-322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930065-7

7 January 2021

10.1016/S1470-2045(17)30065-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28131785%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference